Literature DB >> 3106460

Synthetic growth hormone-releasing hormone (GHRH 1-44) in the differential diagnosis between hypothalamic and pituitary GH deficiency.

M Bozzola, L Tatò, M Cisternino, C Nava, A Valtorta, M Chiesa, F Severi, D Gaburro.   

Abstract

GH response to an iv bolus of growth-hormone-releasing hormone (GHRH 1-44, 2 micrograms/kg iv) was evaluated in 17 prepubertal children with total GH deficiency (GHD), 6 with partial GHD and in 7 prepubertal normal but short children tested as control. GH response to conventional pharmacological (insulin and arginine or L-Dopa) and physiological stimuli (sleep test) and to GHRH test was also compared. GHRH-induced GH peak occurred at variable times and marked heterogeneity in magnitude of the individual responses to this peptide was observed in GHD patients and in controls. GH increases after GHRH with a peak greater than 10 ng/ml suggested an hypothalamic origin of the GHD in 12 patients (8 with total GHD and 4 with partial GHD). A significant difference (p less than 0.025) of GH peak mean following GHRH administration between total GHD children and normal short children was found. GH response to GHRH injection was usually higher than to conventional stimuli. Nevertheless GH peak following GHRH administration was lower than GH peak following conventional stimuli in 6 children (2 partial GHD children and 4 normal ones). A normal short child failed to respond to GHRH test performed twice. GHRH test is an important diagnostic tool in order to point out hypothalamic GHD.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3106460     DOI: 10.1007/BF03346976

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  11 in total

1.  Physiological role of somatostatin in the control of growth hormone and thyrotropin secretion.

Authors:  L Ferland; F Labrie; M Jobin; A Arimura; A V Schally
Journal:  Biochem Biophys Res Commun       Date:  1976-01-12       Impact factor: 3.575

2.  Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour.

Authors:  J Rivier; J Spiess; M Thorner; W Vale
Journal:  Nature       Date:  1982-11-18       Impact factor: 49.962

3.  Differential diagnosis between hypothalamic and pituitary hGH deficiency with the aid of synthetic GH-RH 1-44.

Authors:  Z Laron; R Keret; B Bauman; A Pertzelan; Z Ben-Zeev; D B Olsen; A M Comaru-Schally; A V Schally
Journal:  Clin Endocrinol (Oxf)       Date:  1984-07       Impact factor: 3.478

4.  Stimulation of growth hormone (GH) and somatomedin C in idiopathic GH-deficient subjects by intermittent pulsatile administration of synthetic human pancreatic tumor GH-releasing factor.

Authors:  J L Borges; R M Blizzard; W S Evans; R Furlanetto; A D Rogol; D L Kaiser; J Rivier; W Vale; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1984-07       Impact factor: 5.958

5.  The response of normal subjects and patients with idiopathic growth hormone deficiency to continuous infusion of human pancreatic growth hormone releasing factor 1-44.

Authors:  R R Davies; S J Turner; J M Parkin; D G Johnston
Journal:  Clin Endocrinol (Oxf)       Date:  1984-11       Impact factor: 3.478

6.  A noninvasive functional lesion of the hypothalamo-pituitary axis for the study of growth hormone-releasing factor.

Authors:  W B Wehrenberg; P Brazeau; R Luben; N Ling; R Guillemin
Journal:  Neuroendocrinology       Date:  1983-06       Impact factor: 4.914

7.  Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly.

Authors:  R Guillemin; P Brazeau; P Böhlen; F Esch; N Ling; W B Wehrenberg
Journal:  Science       Date:  1982-11-05       Impact factor: 47.728

8.  Effects on growth hormone secretion following intravenous and subcutaneous injections of growth hormone-releasing factor (hGRF-44 NH2): comparison of immunoreactive plasma GRF levels.

Authors:  G Sassolas; S Biot-Laporte; R Cohen; A Elm Charfi; S Ferry; F Borson
Journal:  Clin Endocrinol (Oxf)       Date:  1985-05       Impact factor: 3.478

9.  Evidence for a limited growth hormone (GH)-releasing hormone (GHRH)-releasable quantity of GH: effects of 6-hour infusions of GHRH on GH secretion in normal man.

Authors:  M L Vance; D L Kaiser; W S Evans; M O Thorner; R Furlanetto; J Rivier; W Vale; G Perisutti; L A Frohman
Journal:  J Clin Endocrinol Metab       Date:  1985-02       Impact factor: 5.958

10.  Idiopathic growth hormone (GH) deficiency, and GH deficiency secondary to hypothalamic germinoma: effect of single and repeated administration of human GH-releasing factor (hGRF) on plasma GH level and endogenous hGRF-like immunoreactivity level in cerebrospinal fluid.

Authors:  K Chihara; Y Kashio; H Abe; N Minamitani; H Kaji; T Kita; T Fujita
Journal:  J Clin Endocrinol Metab       Date:  1985-02       Impact factor: 5.958

View more
  3 in total

1.  GHRH-test in short children with "non classic" GH deficiency. A comparison with "classic" GH deficiency and short normal stature.

Authors:  G Saggese; G Cesaretti; N Giannessi; L Cinquanta; C Bracaloni; C Cioni; G Di Spigno; R Di Porto
Journal:  J Endocrinol Invest       Date:  1990-06       Impact factor: 4.256

2.  Long term growth hormone (GH)-releasing hormone and biosynthetic GH therapy in GH-deficient children: comparison of therapeutic effectiveness.

Authors:  M Bozzola; I Biscaldi; M Cisternino; F Severi; A Balsamo; E Cacciari; C Pellini; G Chiumello; G L Spadoni; B Boscherini
Journal:  J Endocrinol Invest       Date:  1990-03       Impact factor: 4.256

3.  Diagnostic value of growth hormone-releasing hormone test in children and adolescents with idiopathic growth hormone deficiency.

Authors:  T Arrigo; F Martino; F Lombardo; N Laforgia; A Acquafredda; R Russo; L Cavallo; F De Luca
Journal:  Eur J Pediatr       Date:  1992-04       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.